# Astragaloside IV

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/astragaloside-iv
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-19
**Evidence Score:** 8 / 10
**Category:** Compound
**Also Known As:** AS-IV, 3-O-β-D-xylopyranosyl-6-O-β-D-glucopyranosyl-cycloastragenol, Cycloastragenol 3-O-β-D-xylopyranosyl-6-O-β-D-glucopyranoside, Astragaloside A4, Huangqi Saponin IV, AST-IV

## Overview

Astragaloside IV is a triterpene saponin extracted from Astragalus membranaceus root that demonstrates [anti-inflammatory](/ingredients/condition/inflammation) and [antioxidant](/ingredients/condition/antioxidant) properties. It works primarily by inhibiting NF-κB signaling pathways and activating Nrf2-mediated antioxidant responses.

## Health Benefits

• [Anti-inflammatory](/ingredients/condition/inflammation) effects through NF-κB inhibition and TLR4/MyD88 pathway suppression (preclinical evidence only)
• Antioxidant activity via [reactive oxygen species](/ingredients/condition/antioxidant) scavenging and Nrf2 activation (in vitro studies)
• Potential anticancer properties through cell cycle regulation and apoptosis modulation at 50-100 ng/mL (cell culture models)
• Cardioprotective effects suggested through multiple pathway modulation (animal studies only)
• [Immune system](/ingredients/condition/immune-support) support aligned with traditional qi-tonifying applications (traditional use, lacks clinical validation)

## Mechanism of Action

Astragaloside IV suppresses [inflammatory](/ingredients/condition/inflammation) responses by blocking NF-κB nuclear translocation and inhibiting the TLR4/MyD88 signaling cascade. It enhances cellular [antioxidant](/ingredients/condition/antioxidant) defenses through Nrf2 pathway activation, increasing expression of antioxidant enzymes like HO-1 and NQO1. The compound also modulates cell cycle proteins and promotes apoptosis in abnormal cells through p53 and caspase pathway activation.

## Clinical Summary

Current evidence for astragaloside IV is primarily limited to preclinical studies and in vitro research. Animal studies have shown [anti-inflammatory](/ingredients/condition/inflammation) effects at doses of 10-50 mg/kg, with significant reductions in inflammatory markers like TNF-α and IL-6. [Antioxidant activity](/ingredients/condition/antioxidant) has been demonstrated in cell culture studies using concentrations of 1-100 μM. No human clinical trials have been published to date, making clinical efficacy and optimal dosing unclear.

## Nutritional Profile

Astragaloside IV is a purified triterpenoid saponin compound (cycloartane-type), not a whole food ingredient, therefore it contains no meaningful macronutrients, dietary fiber, vitamins, or minerals in its isolated form. Molecular weight: 784.98 g/mol (C41H68O14). It is the primary bioactive glycoside extracted from Astragalus membranaceus root, typically present at 0.01–0.04% by dry weight in raw root material. As an isolated compound, it is administered in concentrations ranging from 25–100 mg/kg in preclinical animal models and at 50–100 ng/mL in cell culture studies. Bioavailability is notably poor when taken orally: absolute oral bioavailability is estimated at approximately 2.2–3.8% in rodent models due to low [intestinal permeability](/ingredients/condition/gut-health) and extensive first-pass [metabolism](/ingredients/condition/weight-management), with a Tmax of approximately 0.5–1 hour and half-life of roughly 2–4 hours. Gut microbiota partially hydrolyze the glycoside moieties, producing aglycone metabolites (cycloastragenol) which may exhibit enhanced membrane permeability. Lipophilicity is low-to-moderate (logP approximately 0.3), limiting passive diffusion. Nanoparticle and phospholipid complex formulations have been shown in preclinical studies to increase bioavailability by 3–5 fold. No caloric, protein, fat, or carbohydrate content is nutritionally relevant in supplemental doses (typically 5–50 mg per dose in commercial preparations).

## Dosage & Preparation

No clinically studied dosage ranges for humans have been established. Preclinical studies use concentrations of 50-100 ng/mL in cell culture models, but these cannot be extrapolated to human dosing. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Safety data for astragaloside IV in humans is limited due to lack of clinical trials. Animal studies suggest good tolerability at therapeutic doses, though higher concentrations may cause gastrointestinal upset. No specific drug interactions have been documented, but theoretical interactions may exist with immunosuppressive medications due to immune-modulating effects. Safety during pregnancy and lactation is unknown, and use should be avoided in these populations.

## Scientific Research

The research dossier reveals a critical gap: no human clinical trials, RCTs, or meta-analyses for Astragaloside IV were identified. All available evidence comes from preclinical studies using in vitro and animal models, with researchers calling for human trials to validate observed anticancer, [anti-inflammatory](/ingredients/condition/inflammation), and cardioprotective effects.

## Historical & Cultural Context

Astragaloside IV is the primary active constituent in Astragalus membranaceus, used in Traditional Chinese Medicine for centuries to tonify qi and treat fatigue, immune deficiency, and [cardiovascular](/ingredients/condition/heart-health) issues. Modern pharmacological research on its anti-tumor, [anti-inflammatory](/ingredients/condition/inflammation), and [antioxidant](/ingredients/condition/antioxidant) properties aligns with these traditional applications.

## Synergistic Combinations

Astragalus polysaccharides, Ginsenosides, Quercetin, Resveratrol, Cordyceps

## Frequently Asked Questions

### What is the recommended dose of astragaloside IV for humans?

No clinically established human dosage exists for astragaloside IV. Preclinical research has used concentrations of 50–100 ng/mL in cell culture models, but these figures cannot be reliably extrapolated to human supplementation. Supplement labels may list doses ranging from 40–100 mg of standardised Astragalus extract, but these lack clinical validation for astragaloside IV specifically. Until human trials are conducted, there is no evidence-based dosing recommendation. Always consult a qualified healthcare provider before use.

### Does astragaloside IV actually work in humans or only in lab studies?

Currently, astragaloside IV has only been studied in preclinical settings — meaning in vitro cell culture models and animal studies. No randomised controlled trials or human clinical studies have been identified. While the mechanistic evidence is promising, particularly regarding NF-κB inhibition and Nrf2 activation, these findings cannot be assumed to translate directly to human outcomes. Researchers have explicitly called for human trials to validate the anti-inflammatory, cardioprotective, and other effects observed preclinically.

### Is astragaloside IV safe to take daily?

The long-term safety profile of astragaloside IV in humans has not been established through clinical trials. Preclinical animal and cell culture studies have not flagged overt toxicity at studied concentrations, but this does not confirm human safety. Because no human pharmacokinetic, tolerability, or adverse effect data are available, daily supplementation carries unknown risks. Individuals with autoimmune conditions, those on immunosuppressants, or pregnant and breastfeeding women should be especially cautious and consult a healthcare provider before use.

### Can astragaloside IV help with heart health?

Animal studies suggest astragaloside IV may exert cardioprotective effects through modulation of multiple signalling pathways, including NF-κB inhibition and antioxidant enzyme upregulation via Nrf2 activation. These mechanisms could theoretically reduce oxidative stress and inflammation implicated in cardiovascular disease. However, all current evidence is from animal models only. No human clinical trials have confirmed cardioprotective benefits in people. It would be premature to use astragaloside IV specifically for heart health until robust human data are available.

### What does astragaloside IV do in the body at a molecular level?

Astragaloside IV is a triterpene saponin that targets several key intracellular pathways. It blocks NF-κB nuclear translocation, suppressing pro-inflammatory gene expression, and inhibits the TLR4/MyD88 signalling cascade involved in innate immune activation. It also activates the Nrf2 pathway, upregulating antioxidant enzymes such as HO-1 and NQO1 to neutralise reactive oxygen species. Additionally, it modulates cell cycle regulators and activates p53 and caspase pathways to promote apoptosis in abnormal cells, based on in vitro evidence.

### Can I take astragaloside IV with other supplements or medications?

There are no clinically studied drug or supplement interaction data specifically for astragaloside IV in humans. Because it modulates immune signalling pathways, it may theoretically interact with immunosuppressant medications, anticoagulants, or other anti-inflammatory agents. Its Nrf2-activating properties could also influence the metabolism of certain drugs via cytochrome P450 enzyme pathways, though this has not been confirmed in humans. Until interaction studies are conducted, caution is warranted. Always disclose all supplements to your healthcare provider before combining them with medications.

### How does astragaloside IV differ from cycloastragenol?

Astragaloside IV and cycloastragenol are both triterpene saponins derived from Astragalus membranaceus, but they are distinct compounds. Cycloastragenol is a hydrolysed metabolite of astragaloside IV and has been more widely studied for its potential telomerase-activating properties. Astragaloside IV has garnered attention for its anti-inflammatory effects via NF-κB inhibition and antioxidant activity through Nrf2 activation. While structurally related, their biological activities, research profiles, and proposed mechanisms differ, and neither compound has established human clinical trial evidence.

### Does astragaloside IV boost immune function?

Traditional use of Astragalus membranaceus in Chinese medicine associates the root with qi tonification and immune support, and astragaloside IV is considered one of its key bioactive compounds. Preclinical data suggest it modulates immune signalling by inhibiting TLR4/MyD88 pathways and suppressing NF-κB activity, which could influence inflammatory immune responses. However, these findings come exclusively from in vitro and animal models. No human clinical trials have validated immune-boosting effects for astragaloside IV specifically. The traditional use should not be conflated with clinically proven immune benefits.

### Is astragaloside IV backed by human clinical trials?

No human clinical trials, randomised controlled trials, or meta-analyses have been completed for astragaloside IV as of current research. All available evidence comes from in vitro cell culture studies and animal models. While these preclinical findings on anti-inflammatory, antioxidant, and cardioprotective effects are promising, they cannot be directly applied to humans. Researchers have explicitly called for human trials to validate these observations. Consumers should treat any health claims about astragaloside IV with caution until clinical evidence is established.

### How does astragaloside IV reduce inflammation?

Astragaloside IV reduces inflammation through two primary preclinical mechanisms. First, it blocks NF-κB nuclear translocation, a key step that would otherwise activate pro-inflammatory gene expression. Second, it suppresses the TLR4/MyD88 signalling cascade, which plays a central role in triggering innate immune inflammatory responses. These dual mechanisms have been demonstrated in cell culture and animal studies, suggesting broad anti-inflammatory potential. However, no human studies have confirmed whether these mechanisms produce meaningful anti-inflammatory effects at achievable blood concentrations in people.

### Can astragaloside IV help with cancer?

Potential anticancer properties of astragaloside IV have been observed only in cell culture models at concentrations of 50–100 ng/mL. The compound appears to modulate cell cycle regulation and promote apoptosis in abnormal cells through activation of p53 and caspase pathways. These are early-stage laboratory findings and have not been replicated in human clinical trials. Astragaloside IV should not be considered a cancer treatment or preventive agent. Anyone with cancer or cancer risk should consult a qualified oncologist before considering this supplement.

### What is the difference between astragaloside IV and Astragalus root extract?

Astragalus root extract is a broad preparation derived from Astragalus membranaceus root containing hundreds of bioactive compounds including polysaccharides, flavonoids, and multiple saponins. Astragaloside IV is one specific triterpene saponin isolated from that root. Standardised astragaloside IV supplements deliver a concentrated, defined compound, allowing more targeted study of its mechanisms such as NF-κB inhibition and Nrf2 activation. In contrast, whole root extracts provide a wider array of compounds that may work synergistically. Neither has robust human clinical trial data confirming efficacy for specific health conditions.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*